Details for New Drug Application (NDA): 011287
✉ Email this page to a colleague
NDA 011287 describes KAYEXALATE, which is a drug marketed by Concordia and is included in one NDA. Additional details are available on the KAYEXALATE profile page.
The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
Summary for 011287
| Tradename: | KAYEXALATE |
| Applicant: | Concordia |
| Ingredient: | sodium polystyrene sulfonate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;ORAL, RECTAL | Strength | 453.6GM/BOT **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
